Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + cyclophosphamide + epidoxorubicin + lonidamine
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
The combination of 5-fluorouracil, epidoxorubicin, cyclophosphamide (FEC), and lonidamine is an investigational chemotherapy regimen primarily studied for breast cancer treatment. FEC is a well-established conventional cytotoxic chemotherapy regimen. 5-fluorouracil, epidoxorubicin, and cyclophosphamide are typically administered intravenously on day 1 of a 21-day cycle, with dosages for fluorouracil and cyclophosphamide ranging from 500-600 mg/m² and epidoxorubicin from 50-90 mg/m². Lonidamine is a metabolic inhibitor that targets cancer cell energy metabolism, and its addition to FEC is part of an investigational approach to potentially enhance the efficacy of the chemotherapy by targeting altered metabolic pathways in cancer cells.
- Other names
- FEC + Lonidamine
02
Targets
DNATS (Thymidylate synthase)MCT4 (Monocarboxylate transporter 4)TOP2A (DNA topoisomerase II)HK2 (Hexokinase Type II)
Beyond the preview
Go deeper on 5-fluorouracil + cyclophosphamide + epidoxorubicin + lonidamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + cyclophosphamide + epidoxorubicin + lonidamine.